Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke

@article{Diener2018NonvitaminKOA,
  title={Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke},
  author={Hans Christoph Diener and George Ntaios and Martin O’Donnell and J. Donald Easton},
  journal={Expert Opinion on Pharmacotherapy},
  year={2018},
  volume={19},
  pages={1597 - 1602}
}
ABSTRACT Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative reduction in stroke risk compared with placebo. Mortality is reduced by 26%. VKA have a number of well-documented shortcomings which were overcome by non-vitamin-K oral anticoagulants (NOACs). Areas covered: Results of randomized trials for four NOACs (apixaban… 
Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
TLDR
The four NOACs had broadly similar efficacy for the major outcomes in secondary stroke prevention and two large trials tested the hypothesis that NOacs are more effective than 100 mg aspirin in patients with ESUS showed a significant benefit of the NOAC over aspirin.
Stroke prevention in atrial fibrillation : update with NOAC treatment and the impact of reversal
TLDR
Results from RCTs and real-world analyses consistently demonstrate the safety and efficacy profiles of dabigatran in patients with atrial fibrillation and Idarucizumab has been established as an effective reversal agent for dabig atran-treated patients and can be administered promptly and safely in a mobile, pre-hospital setting.
Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study
TLDR
The PRODAST study will provide important real-world data on safety and efficacy of antithrombotic therapy after acute stroke and TIA in patients with AF and compare the three-month rates of major haemorrhagic events between early versus late administration of dabigatran or treatment with vitamin-K antagonists.
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.
Economy- and Social-Based Strategies for Anticoagulation of Patients with Atrial Fibrillation.
TLDR
Evaluating the costs related to anticoagulant therapy in a one-year period and the quality of life of atrial fibrillation patients treated in a public university hospital concluded that a nearly 40% reduction in the price of DOACs could make it feasible to incorporate these drugs into the Brazilian public health system.
Estimation of the economic burden of atrial fibrillation-related stroke in Greece
TLDR
It seems that ensuring efficient reallocation of resources in appropriate prevention and early intervention strategies could decrease AF-related stroke’s burden but also enhance healthcare systems’ efficiency.
Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.
TLDR
With the availability of back issues online for Thrombosis & Haemostasis ever since the original first published issue in 1957, it was felt that stroke could be an initial special focus, given the publication on this topic in Volume1, Issue1 of this journal.
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery.
TLDR
Detailed structure-activity relationship studies using a C-ring-truncated version of Vorapaxar culminated in the discovery of three leads, represented as 13, 14, and 23, which possessed favorable pharmacokinetic properties and an off-target profile.
Conservative management of massive rivaroxaban overdose: A case report and literature review
In the cases of acute rivaroxaban overdose, conservative management without prothrombin complex concentrate or other coagulation factors may be sufficient if renal function is normal and there is no
...
...

References

SHOWING 1-10 OF 44 REFERENCES
Apixaban versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
TLDR
Evidence supports the use of particular NOACs and/or particular doses of anticoagulant for specific subgroups of patients with AF, and suggests the appropriate choice of treatment for these subgroups will help to promote optimal clinical outcomes.
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
TLDR
A review of analyses of subgroups of patients from trials of vitamin K antagonists vs. NOACs for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
TLDR
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Apixaban in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Dabigatran versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
...
...